10-Q: Arcutis Biotherapeutics Q3 2025: Revenue Soars, Net Income Returns

Arcutis Biotherapeutics reports significant revenue growth and a return to net income in Q3 2025, driven by strong ZORYVE product sales and strategic approvals.

Summary

• Achieved net income of $7.41 million for Q3 2025, a significant improvement from a net loss of $41.54 million in Q3 2024.
• Total revenues for Q3 2025 reached $99.22 million, up 122% from $44.76 million in Q3 2024.
• Product revenue, net, for ZORYVE cream 0.3% increased by 38% to $30.49 million in Q3 2025.
• Product revenue, net, for ZORYVE foam increased by 146% to $49.78 million in Q3 2025.
• Product revenue, net, for ZORYVE cream 0.15% increased by 673% to $18.95 million in Q3 2025.
• For the nine months ended September 30, 2025, total revenues were $246.57 million, up from $125.18 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, was $33.54 million, a substantial reduction from $129.25 million in the prior year period.
• Cash, cash equivalents, restricted cash, and marketable securities totaled $191.4 million as of September 30, 2025, down from $228.6 million as of December 31, 2024.
• Outstanding long-term debt was $100.0 million as of September 30, 2025.
• Received FDA approval for ZORYVE cream 0.05% for mild to moderate atopic dermatitis in children ages 2 to 5 years in October 2025, with commercial launch planned for October 2025.
• Submitted a supplemental New Drug Application (sNDA) to FDA in September 2025 to expand the ZORYVE cream 0.3% indication for plaque psoriasis in children down to age 2.
• Initiated INTEGUMENT-INFANT, a Phase 2 study for ZORYVE cream 0.05% in infants (3 months to less than 2 years) with atopic dermatitis in June 2025.
• Halted further development of the ARQ-255 (topical JAK inhibitor) program after Phase 1b study completion in mid-2025.
• Submitted an Investigational New Drug (IND) application for ARQ-234 (CD200R agonist) in July 2025, with a Phase 1 study anticipated in Q1 2026.

Sentiment

Score: 8

Explanation: The company demonstrated strong commercial execution with significant revenue growth across its ZORYVE product portfolio, leading to a return to net income in Q3 2025. Multiple recent regulatory approvals and pipeline advancements, including the planned ARQ-234 Phase 1 study, indicate positive momentum. While an accumulated deficit and cash burn persist, the Q3 performance and strategic initiatives are highly encouraging.

Positives

• Achieved net income of $7.41 million in Q3 2025, a significant turnaround from a net loss of $41.54 million in Q3 2024.
• Total revenues increased by 122% to $99.22 million in Q3 2025 compared to Q3 2024.
• Strong product revenue growth across all ZORYVE formulations: ZORYVE cream 0.3% up 38%, ZORYVE foam up 146%, and ZORYVE cream 0.15% up 673% in Q3 2025.
• Multiple recent FDA and Health Canada approvals and commercial launches for ZORYVE products, expanding market reach and indications.
• Reduced net loss for the nine months ended September 30, 2025, to $33.54 million from $129.25 million in the prior year.
• Successfully made a $100.0 million principal paydown on the Loan Agreement in October 2024, reducing outstanding debt.
• Maintained compliance with all covenants under the Loan Agreement as of September 30, 2025.
• Anticipates commencing a Phase 1 study for ARQ-234 in Q1 2026, indicating pipeline progression.
• Entered into a co-promotion agreement with Kowa Pharmaceuticals, Inc. in July 2024 to expand ZORYVE marketing to primary care practitioners and pediatricians.

Negatives

• Continued accumulated deficit of $1,155.5 million as of September 30, 2025.
• Cash, cash equivalents, restricted cash, and marketable securities decreased to $191.4 million as of September 30, 2025, from $228.6 million as of December 31, 2024.
• Net cash used in operating activities was $31.8 million for the nine months ended September 30, 2025.
• Halted further development of the ARQ-255 (topical JAK inhibitor) program after Phase 1b study completion, indicating a pipeline setback.
• Other income, net, decreased by $2.1 million in Q3 2025 and $6.6 million for the nine months ended September 30, 2025, primarily due to lower cash balances and investment yields.
• Interest expense, while decreasing, remains significant at $3.07 million for Q3 2025 and $9.08 million for the nine months ended September 30, 2025.

Risks

• Uncertainty regarding the extent of future net income or losses, with the possibility of continued losses.
• Reliance on third parties for nonclinical studies, clinical trials, manufacturing, and supply, many of whom are single-source suppliers.
• Inability to obtain additional financing on acceptable terms or at all, which could require curtailing planned activities and adversely impact business objectives.
• The successful development of product candidates is highly uncertain, and the nature, timing, or costs to complete remaining development cannot be reasonably estimated.
• Exposure to market risks, primarily interest rate sensitivities, which could increase annual interest expense by approximately $1.0 million for every 100 basis point increase in SOFR.
• Exposure to foreign currency exchange risk due to Canadian subsidiary operations.
• Potential adverse effects from changes in tax laws or regulations, such as the 'One Big Beautiful Bill Act' signed on July 4, 2025, which includes cuts to Medicaid spending that could result in lower revenue for life science companies.
• Ongoing legal proceedings, including a patent infringement lawsuit against Padagis and oppositions filed by Teva Pharmaceutical Industries Ltd. against European patents, could result in unfavorable outcomes, defense costs, and diversion of management resources.
• Inherent limitations on the effectiveness of internal controls and procedures, which may not prevent or detect all errors and fraud.

Future Outlook

The company expects to continue incurring significant expenses for the commercialization of ZORYVE and the advancement of its product candidates and label extensions through clinical trials, regulatory submissions, and commercialization. Clinical development spend will focus on ARQ-234 and ZORYVE label expansions. While not anticipating the need for additional funds from financings for current planned operations, the company acknowledges that if available capital resources and anticipated future cash flows are insufficient, it may need to raise additional capital through equity or debt financings or collaboration agreements. A Phase 1 study for ARQ-234 is anticipated to commence in Q1 2026, and ZORYVE cream 0.05% is planned for commercial launch in October 2025.

Management Comments

• We believe we have built a leading platform for dermatologic product development and commercialization.
• Our strategy is to focus on validated biological targets, and to use our drug development platform and deep dermatology expertise to develop and commercialize differentiated products that have the potential to address the major shortcomings of existing therapies in our targeted indications.
• We believe this strategy uniquely positions us to rapidly advance our goal of bridging the treatment innovation gap in dermatology, while maximizing our probability of technical success and financial resources.
• While we generated net income for the quarter ended September 30, 2025, the extent of any net income or losses for future periods is uncertain and we may continue to incur net losses in future periods.
• We expect to continue to incur significant expenses as we commercialize ZORYVE, and as we advance our product candidates and label extensions through clinical trials, regulatory submissions and commercialization.
• We expect to incur commercialization expenses related to the sales, marketing, manufacturing, and distribution of ZORYVE, while we focus our clinical development spend on ARQ-234 and ZORYVE label expansions.
• While we do not anticipate the need to obtain funds through financings or other sources to support our current planned operations, if our available cash and marketable securities balances, amounts available under the Loan Agreement, and anticipated future cash flows from operations are insufficient to cover these expenses, we may need to fund our operations through equity or debt financings or other sources, such as future potential collaboration agreements.

Industry Context

The company operates in the biopharmaceutical industry, specifically focusing on dermatological diseases with high unmet medical needs. The launch of ZORYVE foam as the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades highlights innovation in the dermatology market. The co-promotion agreement with Kowa Pharmaceuticals leverages existing primary care sales forces, a common strategy in the pharmaceutical industry to expand market penetration for approved products. The development of ARQ-234 for atopic dermatitis, a CD200R agonist, indicates a focus on novel biological targets, aligning with broader industry trends towards targeted therapies for immune-mediated conditions. The 'One Big Beautiful Bill Act' and its potential impact on Medicaid spending reflect a changing regulatory and reimbursement landscape that could affect life science companies.

Legal Proceedings

• Filed a patent infringement lawsuit against Padagis Israel Pharmaceuticals Ltd., Padagis US LLC, and Padagis LLC on March 27, 2024, regarding ZORYVE 0.3% cream.
• The court stayed the Padagis case on April 3, 2025, and cancelled all case deadlines, extending the 30-month FDA approval stay.
• Teva Pharmaceutical Industries Ltd. filed oppositions with the European Patent Office against European Patent Nos. EP 3634380 B1 (September 20, 2024) and EP 3684334 B1 (August 13, 2024), related to topical roflumilast compositions.
• Oral proceedings for Teva's oppositions are scheduled for January 8, 2026, and December 4, 2025.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth and return to net income, potential for future growth from pipeline and expanded indications. Risk of dilution if future equity financing is needed.
• Employees: Continued investment in R&D and commercialization efforts suggests stable to growing employment opportunities. Stock-based compensation is a significant component of compensation.
• Customers (Patients/Prescribers): Expanded access to ZORYVE products through new approvals (e.g., ZORYVE cream 0.05% for younger children, ZORYVE foam for scalp psoriasis) and increased commercialization efforts (Kowa partnership).
• Suppliers: Increased demand for ZORYVE products will likely benefit third-party manufacturers and suppliers.
• Creditors: The $100.0 million principal paydown on the Loan Agreement and compliance with covenants are positive for creditors. The ability to draw additional tranches C-1 and C-2 provides flexibility.

Next Steps

• Commercially launch ZORYVE cream 0.05% in October 2025 for mild to moderate atopic dermatitis in children ages 2 to 5 years.
• Continue development of ARQ-234, with a Phase 1 study anticipated in Q1 2026.
• Continue Phase 2 study (INTEGUMENT-INFANT) for ZORYVE cream 0.05% in infants (3 months to less than 2 years) with atopic dermatitis.
• Await FDA decision on sNDA for ZORYVE cream 0.3% to expand indication for plaque psoriasis in children down to age 2.
• Oral proceedings concerning Teva's oppositions to European Patent Nos. EP 3634380 B1 and EP 3684334 B1 scheduled for January 8, 2026, and December 4, 2025, respectively.
• Potentially draw down tranche C-1 and C-2 term loans, subject to revenue covenants, before their expiration dates (March 31, 2026, and June 30, 2026).

Key Dates

Recommendation

The company demonstrated exceptional commercial momentum in Q3 2025, achieving a significant 122% increase in total revenue and a return to net income. The strong performance of the ZORYVE franchise, driven by multiple recent FDA and Health Canada approvals and expanded indications, indicates robust market acceptance and growth potential. While an accumulated deficit remains and cash balances have decreased, the substantial reduction in net loss for the nine-month period and the strategic pipeline advancements (ARQ-234 IND submission, ZORYVE label expansions) suggest a positive trajectory. The company's ability to manage its debt and its strategic co-promotion agreement further strengthen its market position. The current performance and future prospects make it an attractive investment.

Keywords

Dermatology, Biopharmaceutical, ZORYVE, Roflumilast, Psoriasis, Atopic Dermatitis, Seborrheic Dermatitis, PDE4 inhibitor, ARQ-234, CD200R, SEC Filing, 10-Q, Financial Results, Product Revenue, Clinical Trials, FDA Approval, Health Canada, Patent Litigation